These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 28027586)

  • 1. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis.
    McCommis KS; Hodges WT; Brunt EM; Nalbantoglu I; McDonald WG; Holley C; Fujiwara H; Schaffer JE; Colca JR; Finck BN
    Hepatology; 2017 May; 65(5):1543-1556. PubMed ID: 28027586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism.
    Vigueira PA; McCommis KS; Hodges WT; Schweitzer GG; Cole SL; Oonthonpan L; Taylor EB; McDonald WG; Kletzien RF; Colca JR; Finck BN
    Exp Physiol; 2017 Aug; 102(8):985-999. PubMed ID: 28597936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
    Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
    J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism.
    Ferguson D; Eichler SJ; Yiew NKH; Colca JR; Cho K; Patti GJ; Shew TM; Lutkewitte AJ; Mukherjee S; McCommis KS; Niemi NM; Finck BN
    Mol Metab; 2023 Apr; 70():101694. PubMed ID: 36801448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis.
    Colca JR; McDonald WG; Adams WJ
    Expert Opin Investig Drugs; 2018 Jul; 27(7):631-636. PubMed ID: 29950116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide.
    Kamm DR; Pyles KD; Sharpe MC; Healy LN; Colca JR; McCommis KS
    J Biol Chem; 2021; 296():100807. PubMed ID: 34022222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nobiletin mitigates hepatocytes death, liver inflammation, and fibrosis in a murine model of NASH through modulating hepatic oxidative stress and mitochondrial dysfunction.
    Li S; Li X; Chen F; Liu M; Ning L; Yan Y; Zhang S; Huang S; Tu C
    J Nutr Biochem; 2022 Feb; 100():108888. PubMed ID: 34695558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
    Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
    Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
    Widjaja AA; Singh BK; Adami E; Viswanathan S; Dong J; D'Agostino GA; Ng B; Lim WW; Tan J; Paleja BS; Tripathi M; Lim SY; Shekeran SG; Chothani SP; Rabes A; Sombetzki M; Bruinstroop E; Min LP; Sinha RA; Albani S; Yen PM; Schafer S; Cook SA
    Gastroenterology; 2019 Sep; 157(3):777-792.e14. PubMed ID: 31078624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
    Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
    Elife; 2023 Jan; 12():. PubMed ID: 36648330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).
    Sharma RS; Harrison DJ; Kisielewski D; Cassidy DM; McNeilly AD; Gallagher JR; Walsh SV; Honda T; McCrimmon RJ; Dinkova-Kostova AT; Ashford MLJ; Dillon JF; Hayes JD
    Cell Mol Gastroenterol Hepatol; 2018 Mar; 5(3):367-398. PubMed ID: 29552625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic Mitochondrial SAB Deletion or Knockdown Alleviates Diet-Induced Metabolic Syndrome, Steatohepatitis, and Hepatic Fibrosis.
    Win S; Min RWM; Zhang J; Kanel G; Wanken B; Chen Y; Li M; Wang Y; Suzuki A; Aung FWM; Murray SF; Aghajan M; Than TA; Kaplowitz N
    Hepatology; 2021 Dec; 74(6):3127-3145. PubMed ID: 34331779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
    Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
    J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
    Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
    Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.
    Cai CX; Buddha H; Castelino-Prabhu S; Zhang Z; Britton RS; Bacon BR; Neuschwander-Tetri BA
    Dig Dis Sci; 2017 Apr; 62(4):968-978. PubMed ID: 28194671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle-Mediated RNA Therapy Attenuates Nonalcoholic Steatohepatitis and Related Fibrosis by Targeting Activated Hepatic Stellate Cells.
    Zhang C; Teng Y; Li F; Ho W; Bai X; Xu X; Zhang XQ
    ACS Nano; 2023 Aug; 17(15):14852-14870. PubMed ID: 37490628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-β1/Smad signaling pathway.
    Ni XX; Li XY; Wang Q; Hua J
    J Physiol Biochem; 2021 Feb; 77(1):35-45. PubMed ID: 33188625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice.
    Gupte AA; Liu JZ; Ren Y; Minze LJ; Wiles JR; Collins AR; Lyon CJ; Pratico D; Finegold MJ; Wong ST; Webb P; Baxter JD; Moore DD; Hsueh WA
    Hepatology; 2010 Dec; 52(6):2001-11. PubMed ID: 20938947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis.
    Zhou J; Tripathi M; Ho JP; Widjaja AA; Shekeran SG; Camat MD; James A; Wu Y; Ching J; Kovalik JP; Lim KH; Cook SA; Bay BH; Singh BK; Yen PM
    Thyroid; 2022 Jun; 32(6):725-738. PubMed ID: 35317606
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.